Imatinib Grindeks (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, locking them in an inactive state. This blocks downstream signaling that promotes cell proliferation and survival, leading to tumor cell death.

The dosage of Imatinib Grindeks is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, and tolerability. Only a qualified healthcare professional should determine the appropriate regimen.

Imatinib is classified as contraindicated in pregnancy unless the potential benefit justifies the risk to the fetus. It is also not recommended during breastfeeding because it may be excreted in milk. Patients should discuss reproductive plans with their physician.

To place an order, submit an enquiry on the Imatinib Grindeks product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard of care for its approved indications. Newer agents such as dasatinib or nilotinib may offer activity against certain resistant mutations, but Imatinib retains a well‑characterized safety profile and extensive clinical experience.

Store Imatinib Grindeks tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and avoid exposure to extreme temperatures.

Imatinib Grindeks is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare provider.

Serious adverse events include hepatotoxicity, cardiotoxicity (reduced left‑ventricular ejection fraction), and severe neutropenia. Patients should be monitored regularly for liver function, cardiac status, and blood counts to detect these risks early.

Imatinib Grindeks should be avoided in patients with known hypersensitivity to imatinib or any of its excipients, and in individuals with severe hepatic impairment unless benefits outweigh risks. It is also contraindicated during pregnancy unless absolutely necessary.